Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda plus radiotherapy in rectosigmoid carcinoma
NCT00216424Phase 4Terminated
- Sponsor
- James A. Haley Veterans' Hospital
- Start
- Feb 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of capecitabine in rectosigmoid carcinoma, sponsored by James A. Haley Veterans' Hospital. Started Feb 2005; status: terminated.
02
Drugs
capecitabine
03
Conditions
rectosigmoid carcinoma
Beyond the preview
Go deeper on NCT00216424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216424.